However, a more recent study that targeted the G12S mutation variant of the KRAS gene in lung cancer cell line A549 using this CRISPR interference (CRISPRi) system, showed that dCas9-KRAB was outperformed by its wild-type SpCas9 counterpart as a potential therapeutic tool for tumor inhibition [29]. Here, KRAS is linked to lung carcinoma.